ID   PARP1_RAT               Reviewed;        1014 AA.
AC   P27008; O35937;
DT   01-AUG-1992, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   07-APR-2021, entry version 200.
DE   RecName: Full=Poly [ADP-ribose] polymerase 1;
DE            Short=PARP-1;
DE            EC=2.4.2.30 {ECO:0000250|UniProtKB:P09874};
DE   AltName: Full=ADP-ribosyltransferase diphtheria toxin-like 1;
DE            Short=ARTD1;
DE   AltName: Full=DNA ADP-ribosyltransferase PARP1 {ECO:0000250|UniProtKB:P09874};
DE            EC=2.4.2.- {ECO:0000250|UniProtKB:P09874};
DE   AltName: Full=NAD(+) ADP-ribosyltransferase 1;
DE            Short=ADPRT 1;
DE   AltName: Full=Poly[ADP-ribose] synthase 1;
DE   AltName: Full=Protein poly-ADP-ribosyltransferase PARP1 {ECO:0000250|UniProtKB:P09874};
DE            EC=2.4.2.- {ECO:0000250|UniProtKB:P09874};
GN   Name=Parp1; Synonyms=Adprt;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Monocyte;
RX   PubMed=9385436; DOI=10.1080/15216549700204571;
RA   Beneke S., Meyer R., Buerkle A.;
RT   "Isolation of cDNA encoding full-length rat (Rattus norvegicus) poly (ADP-
RT   ribose) polymerase.";
RL   Biochem. Mol. Biol. Int. 43:755-761(1997).
RN   [2]
RP   SEQUENCE REVISION TO 812.
RA   Beneke S., Meyer R., Buerkle A.;
RL   Submitted (FEB-1998) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-12.
RC   STRAIN=Sprague-Dawley; TISSUE=Prostate;
RX   PubMed=1601134; DOI=10.1016/0014-5793(92)80457-r;
RA   Potvin F., Thibodeau J., Kirkland J.B., Dandenault B., Duchaine C.,
RA   Poirier G.G.;
RT   "Structural analysis of the putative regulatory region of the rat gene
RT   encoding poly(ADP-ribose) polymerase.";
RL   FEBS Lett. 302:269-273(1992).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 515-1014.
RC   STRAIN=Sprague-Dawley; TISSUE=Prostate;
RX   PubMed=2508731; DOI=10.1139/o89-097;
RA   Thibodeau J., Gradwohl G., Dumas C., Clairoux-Moreau S., Brunet G.;
RT   "Cloning of rodent cDNA coding the poly(ADP-ribose) polymerase catalytic
RT   domain and analysis of mRNA levels during the cell cycle.";
RL   Biochem. Cell Biol. 67:653-660(1989).
RN   [6]
RP   INTERACTION WITH NR4A3.
RX   PubMed=25625556; DOI=10.1111/bph.13091;
RA   Feng X.J., Gao H., Gao S., Li Z., Li H., Lu J., Wang J.J., Huang X.Y.,
RA   Liu M., Zou J., Ye J.T., Liu P.Q.;
RT   "The orphan receptor NOR1 participates in isoprenaline-induced cardiac
RT   hypertrophy by regulating PARP-1.";
RL   Br. J. Pharmacol. 172:2852-2863(2015).
CC   -!- FUNCTION: Poly-ADP-ribosyltransferase that mediates poly-ADP-
CC       ribosylation of proteins and plays a key role in DNA repair. Mediates
CC       glutamate, aspartate, serine or tyrosine ADP-ribosylation of proteins:
CC       the ADP-D-ribosyl group of NAD(+) is transferred to the acceptor
CC       carboxyl group of target residues and further ADP-ribosyl groups are
CC       transferred to the 2'-position of the terminal adenosine moiety,
CC       building up a polymer with an average chain length of 20-30 units.
CC       Serine ADP-ribosylation of proteins constitutes the primary form of
CC       ADP-ribosylation of proteins in response to DNA damage. Mainly mediates
CC       glutamate and aspartate ADP-ribosylation of target proteins in absence
CC       of HPF1. Following interaction with HPF1, catalyzes serine ADP-
CC       ribosylation of target proteins; HPF1 conferring serine specificity by
CC       completing the PARP1 active site. Also catalyzes tyrosine ADP-
CC       ribosylation of target proteins following interaction with HPF1. PARP1
CC       initiates the repair of DNA breaks: recognizes and binds DNA breaks
CC       within chromatin and recruits HPF1, licensing serine ADP-ribosylation
CC       of target proteins, such as histones, thereby promoting decompaction of
CC       chromatin and the recruitment of repair factors leading to the
CC       reparation of DNA strand breaks. In addition to base excision repair
CC       (BER) pathway, also involved in double-strand breaks (DSBs) repair:
CC       together with TIMELESS, accumulates at DNA damage sites and promotes
CC       homologous recombination repair by mediating poly-ADP-ribosylation.
CC       Mediates the poly(ADP-ribosyl)ation of a number of proteins, including
CC       itself, APLF and CHFR. In addition to proteins, also able to ADP-
CC       ribosylate DNA: catalyzes ADP-ribosylation of DNA strand break termini
CC       containing terminal phosphates and a 2'-OH group in single- and double-
CC       stranded DNA, respectively. Required for PARP9 and DTX3L recruitment to
CC       DNA damage sites. PARP1-dependent PARP9-DTX3L-mediated ubiquitination
CC       promotes the rapid and specific recruitment of 53BP1/TP53BP1,
CC       UIMC1/RAP80, and BRCA1 to DNA damage sites. Acts as a regulator of
CC       transcription: positively regulates the transcription of MTUS1 and
CC       negatively regulates the transcription of MTUS2/TIP150. Plays a role in
CC       the positive regulation of IFNG transcription in T-helper 1 cells as
CC       part of an IFNG promoter-binding complex with TXK and EEF1A1. Involved
CC       in the synthesis of ATP in the nucleus, together with NMNAT1, PARG and
CC       NUDT5. Nuclear ATP generation is required for extensive chromatin
CC       remodeling events that are energy-consuming.
CC       {ECO:0000250|UniProtKB:P09874}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=NAD(+) + (ADP-D-ribosyl)(n)-acceptor = nicotinamide + (ADP-D-
CC         ribosyl)(n+1)-acceptor.; EC=2.4.2.30;
CC         Evidence={ECO:0000250|UniProtKB:P09874};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-seryl-[protein] + NAD(+) = H(+) + nicotinamide + O-(ADP-D-
CC         ribosyl)-L-seryl-[protein]; Xref=Rhea:RHEA:58232, Rhea:RHEA-
CC         COMP:9863, Rhea:RHEA-COMP:15091, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:17154, ChEBI:CHEBI:29999, ChEBI:CHEBI:57540,
CC         ChEBI:CHEBI:142556; Evidence={ECO:0000250|UniProtKB:P09874};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:58233;
CC         Evidence={ECO:0000250|UniProtKB:P09874};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-aspartyl-[protein] + NAD(+) = 4-O-(ADP-D-ribosyl)-L-
CC         aspartyl-[protein] + nicotinamide; Xref=Rhea:RHEA:54424, Rhea:RHEA-
CC         COMP:9867, Rhea:RHEA-COMP:13832, ChEBI:CHEBI:17154,
CC         ChEBI:CHEBI:29961, ChEBI:CHEBI:57540, ChEBI:CHEBI:138102;
CC         Evidence={ECO:0000250|UniProtKB:P09874};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:54425;
CC         Evidence={ECO:0000250|UniProtKB:P09874};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-glutamyl-[protein] + NAD(+) = 5-O-(ADP-D-ribosyl)-L-
CC         glutamyl-[protein] + nicotinamide; Xref=Rhea:RHEA:58224, Rhea:RHEA-
CC         COMP:10208, Rhea:RHEA-COMP:15089, ChEBI:CHEBI:17154,
CC         ChEBI:CHEBI:29973, ChEBI:CHEBI:57540, ChEBI:CHEBI:142540;
CC         Evidence={ECO:0000250|UniProtKB:P09874};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:58225;
CC         Evidence={ECO:0000250|UniProtKB:P09874};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-tyrosyl-[protein] + NAD(+) = H(+) + nicotinamide + O-(ADP-D-
CC         ribosyl)-L-tyrosyl-[protein]; Xref=Rhea:RHEA:58236, Rhea:RHEA-
CC         COMP:10136, Rhea:RHEA-COMP:15092, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:17154, ChEBI:CHEBI:46858, ChEBI:CHEBI:57540,
CC         ChEBI:CHEBI:142557; Evidence={ECO:0000250|UniProtKB:P09874};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:58237;
CC         Evidence={ECO:0000250|UniProtKB:P09874};
CC   -!- SUBUNIT: Homo- and heterodimer with PARP2. Interacts with APTX (By
CC       similarity). Component of a base excision repair (BER) complex,
CC       containing at least XRCC1, PARP1, PARP2, POLB and LRIG3 (By
CC       similarity). Interacts with SRY (By similarity). The SWAP complex
CC       consists of NPM1, NCL, PARP1 and SWAP70. Interacts with TIAM2 (By
CC       similarity). Interacts with PARP3; leading to activate PARP1 in absence
CC       of DNA (By similarity). Interacts (when poly-ADP-ribosylated) with
CC       CHD1L (via macro domain). Interacts with the DNA polymerase alpha
CC       catalytic subunit POLA1; this interaction functions as part of the
CC       control of replication fork progression. Interacts with EEF1A1 and TXK.
CC       Interacts with RNF4. Interacts with RNF146. Interacts with ZNF423.
CC       Interacts with APLF. Interacts with SNAI1 (via zinc fingers); the
CC       interaction requires SNAI1 to be poly-ADP-ribosylated and non-
CC       phosphorylated (active) by GSK3B. Interacts (when poly-ADP-ribosylated)
CC       with PARP9 (By similarity). Interacts with NR4A3; activates PARP1 by
CC       improving acetylation of PARP1 and suppressing the interaction between
CC       PARP1 and SIRT1 (PubMed:25625556). Interacts (via catalytic domain)
CC       with PUM3; the interaction inhibits the poly-ADP-ribosylation activity
CC       of PARP1 and the degradation of PARP1 by CASP3 following genotoxic
CC       stress. Interacts (via the PARP catalytic domain) with HPF1. Interacts
CC       with ZNF365. Interacts with RRP1B. Interacts with TIMELESS; the
CC       interaction is direct. Interacts with CGAS; leading to impede the
CC       formation of the PARP1-TIMELESS complex (By similarity).
CC       {ECO:0000250|UniProtKB:P09874, ECO:0000250|UniProtKB:P11103,
CC       ECO:0000269|PubMed:25625556}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250|UniProtKB:P09874}. Nucleus,
CC       nucleolus {ECO:0000250|UniProtKB:P09874}. Chromosome
CC       {ECO:0000250|UniProtKB:P09874}. Note=Localizes to sites of DNA damage.
CC       {ECO:0000250|UniProtKB:P09874}.
CC   -!- DOMAIN: The N-terminal disordered region does not act as a key DNA-
CC       binding domain. The WGR and PARP catalytic domains function together to
CC       recruit PARP1 to sites of DNA breaks. The N-terminal disordered region
CC       is only required for activation on specific types of DNA damage.
CC       {ECO:0000250|UniProtKB:Q9UGN5}.
CC   -!- DOMAIN: The WGR domain bridges two nucleosomes, with the broken DNA
CC       aligned in a position suitable for ligation. The bridging induces
CC       structural changes in PARP1 that signal the recognition of a DNA break
CC       to the catalytic domain of PARP1, promoting HPF1 recruitment and
CC       subsequent activation of PARP1, licensing serine ADP-ribosylation of
CC       target proteins. {ECO:0000250|UniProtKB:Q9UGN5}.
CC   -!- PTM: Poly-ADP-ribosylated on glutamate and aspartate residues by
CC       autocatalysis. Poly-ADP-ribosylated by PARP2; poly-ADP-ribosylation
CC       mediates the recruitment of CHD1L to DNA damage sites. ADP-ribosylated
CC       on serine by autocatalysis; serine ADP-ribosylation takes place
CC       following interaction with HPF1 (By similarity). Auto poly-ADP-
CC       ribosylated on serine residues, leading to dissociation of the PARP1-
CC       HPF1 complex from chromatin (By similarity).
CC       {ECO:0000250|UniProtKB:P09874, ECO:0000250|UniProtKB:Q9UGN5}.
CC   -!- PTM: S-nitrosylated, leading to inhibit transcription regulation
CC       activity. {ECO:0000250|UniProtKB:P11103}.
CC   -!- PTM: Phosphorylated by PRKDC and TXK. {ECO:0000250|UniProtKB:P09874}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA46478.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U94340; AAC53544.1; -; mRNA.
DR   EMBL; BC085765; AAH85765.1; -; mRNA.
DR   EMBL; X65496; CAA46477.1; -; Genomic_DNA.
DR   EMBL; X65497; CAA46478.1; ALT_INIT; Genomic_DNA.
DR   PIR; S21163; S21163.
DR   PIR; S26057; S26057.
DR   RefSeq; NP_037195.1; NM_013063.2.
DR   PDB; 2LE0; NMR; -; A=389-487.
DR   PDBsum; 2LE0; -.
DR   SMR; P27008; -.
DR   BioGRID; 247621; 17.
DR   IntAct; P27008; 1.
DR   STRING; 10116.ENSRNOP00000004232; -.
DR   BindingDB; P27008; -.
DR   ChEMBL; CHEMBL4664; -.
DR   CarbonylDB; P27008; -.
DR   iPTMnet; P27008; -.
DR   PhosphoSitePlus; P27008; -.
DR   jPOST; P27008; -.
DR   PaxDb; P27008; -.
DR   PRIDE; P27008; -.
DR   Ensembl; ENSRNOT00000004232; ENSRNOP00000004232; ENSRNOG00000003084.
DR   GeneID; 25591; -.
DR   KEGG; rno:25591; -.
DR   UCSC; RGD:2053; rat.
DR   CTD; 142; -.
DR   RGD; 2053; Parp1.
DR   eggNOG; KOG1037; Eukaryota.
DR   GeneTree; ENSGT00940000156058; -.
DR   HOGENOM; CLU_004841_0_0_1; -.
DR   InParanoid; P27008; -.
DR   OMA; AISDKCT; -.
DR   OrthoDB; 909382at2759; -.
DR   PhylomeDB; P27008; -.
DR   TreeFam; TF316616; -.
DR   Reactome; R-RNO-110362; POLB-Dependent Long Patch Base Excision Repair.
DR   Reactome; R-RNO-2173795; Downregulation of SMAD2/3:SMAD4 transcriptional activity.
DR   Reactome; R-RNO-3108214; SUMOylation of DNA damage response and repair proteins.
DR   Reactome; R-RNO-5685939; HDR through MMEJ (alt-NHEJ).
DR   Reactome; R-RNO-5696394; DNA Damage Recognition in GG-NER.
DR   Reactome; R-RNO-5696395; Formation of Incision Complex in GG-NER.
DR   Reactome; R-RNO-5696400; Dual Incision in GG-NER.
DR   PRO; PR:P27008; -.
DR   Proteomes; UP000002494; Chromosome 13.
DR   Bgee; ENSRNOG00000003084; Expressed in heart and 21 other tissues.
DR   Genevisible; P27008; RN.
DR   GO; GO:0005737; C:cytoplasm; IDA:RGD.
DR   GO; GO:0005739; C:mitochondrion; ISO:RGD.
DR   GO; GO:0016604; C:nuclear body; IEA:Ensembl.
DR   GO; GO:0005635; C:nuclear envelope; ISO:RGD.
DR   GO; GO:0005730; C:nucleolus; ISO:RGD.
DR   GO; GO:0005654; C:nucleoplasm; ISO:RGD.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0032991; C:protein-containing complex; ISO:RGD.
DR   GO; GO:0032993; C:protein-DNA complex; ISO:RGD.
DR   GO; GO:0090734; C:site of DNA damage; ISS:UniProtKB.
DR   GO; GO:0035861; C:site of double-strand break; ISO:RGD.
DR   GO; GO:0005667; C:transcription regulator complex; ISO:RGD.
DR   GO; GO:0003682; F:chromatin binding; ISO:RGD.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL.
DR   GO; GO:0030331; F:estrogen receptor binding; IPI:RGD.
DR   GO; GO:0042826; F:histone deacetylase binding; IPI:RGD.
DR   GO; GO:0042802; F:identical protein binding; ISO:RGD.
DR   GO; GO:0051287; F:NAD binding; IDA:RGD.
DR   GO; GO:0140294; F:NAD DNA ADP-ribosyltransferase activity; ISO:RGD.
DR   GO; GO:0003950; F:NAD+ ADP-ribosyltransferase activity; IDA:RGD.
DR   GO; GO:1990404; F:protein ADP-ribosylase activity; ISS:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; ISO:RGD.
DR   GO; GO:0047485; F:protein N-terminus binding; ISO:RGD.
DR   GO; GO:0070412; F:R-SMAD binding; IPI:BHF-UCL.
DR   GO; GO:0046332; F:SMAD binding; IPI:RGD.
DR   GO; GO:0008134; F:transcription factor binding; ISO:RGD.
DR   GO; GO:0016763; F:transferase activity, transferring pentosyl groups; NAS:RGD.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0006915; P:apoptotic process; ISO:RGD.
DR   GO; GO:1990966; P:ATP generation from poly-ADP-D-ribose; ISS:UniProtKB.
DR   GO; GO:0006284; P:base-excision repair; ISO:RGD.
DR   GO; GO:0048148; P:behavioral response to cocaine; ISO:RGD.
DR   GO; GO:1904646; P:cellular response to amyloid-beta; IMP:RGD.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; ISS:UniProtKB.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; ISO:RGD.
DR   GO; GO:0034599; P:cellular response to oxidative stress; ISO:RGD.
DR   GO; GO:0071451; P:cellular response to superoxide; ISO:RGD.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IMP:RGD.
DR   GO; GO:0034644; P:cellular response to UV; ISO:RGD.
DR   GO; GO:0071294; P:cellular response to zinc ion; IEP:RGD.
DR   GO; GO:0030592; P:DNA ADP-ribosylation; ISS:UniProtKB.
DR   GO; GO:0042769; P:DNA damage response, detection of DNA damage; IDA:RGD.
DR   GO; GO:0006259; P:DNA metabolic process; ISO:RGD.
DR   GO; GO:0006302; P:double-strand break repair; ISS:UniProtKB.
DR   GO; GO:0032042; P:mitochondrial DNA metabolic process; ISO:RGD.
DR   GO; GO:0043504; P:mitochondrial DNA repair; ISO:RGD.
DR   GO; GO:0007005; P:mitochondrion organization; ISO:RGD.
DR   GO; GO:2001170; P:negative regulation of ATP biosynthetic process; ISO:RGD.
DR   GO; GO:0032700; P:negative regulation of interleukin-17 production; ISO:RGD.
DR   GO; GO:1904357; P:negative regulation of telomere maintenance via telomere lengthening; ISO:RGD.
DR   GO; GO:0018424; P:peptidyl-glutamic acid poly-ADP-ribosylation; ISS:UniProtKB.
DR   GO; GO:0018312; P:peptidyl-serine ADP-ribosylation; ISS:UniProtKB.
DR   GO; GO:0010613; P:positive regulation of cardiac muscle hypertrophy; IMP:UniProtKB.
DR   GO; GO:1905168; P:positive regulation of double-strand break repair via homologous recombination; ISS:UniProtKB.
DR   GO; GO:0033148; P:positive regulation of intracellular estrogen receptor signaling pathway; IMP:RGD.
DR   GO; GO:0051901; P:positive regulation of mitochondrial depolarization; IMP:RGD.
DR   GO; GO:1904762; P:positive regulation of myofibroblast differentiation; IMP:RGD.
DR   GO; GO:1901216; P:positive regulation of neuron death; IMP:RGD.
DR   GO; GO:1900182; P:positive regulation of protein localization to nucleus; IMP:RGD.
DR   GO; GO:1903518; P:positive regulation of single strand break repair; ISO:RGD.
DR   GO; GO:0060391; P:positive regulation of SMAD protein signal transduction; IMP:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL.
DR   GO; GO:2000679; P:positive regulation of transcription regulatory region DNA binding; IMP:BHF-UCL.
DR   GO; GO:0006471; P:protein ADP-ribosylation; IDA:RGD.
DR   GO; GO:0070213; P:protein auto-ADP-ribosylation; ISS:UniProtKB.
DR   GO; GO:0016540; P:protein autoprocessing; IDA:RGD.
DR   GO; GO:0036211; P:protein modification process; ISO:RGD.
DR   GO; GO:0070212; P:protein poly-ADP-ribosylation; IMP:BHF-UCL.
DR   GO; GO:0050790; P:regulation of catalytic activity; ISO:RGD.
DR   GO; GO:1903827; P:regulation of cellular protein localization; ISO:RGD.
DR   GO; GO:0044030; P:regulation of DNA methylation; IMP:RGD.
DR   GO; GO:0040009; P:regulation of growth rate; ISO:RGD.
DR   GO; GO:1903376; P:regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway; IMP:RGD.
DR   GO; GO:1903516; P:regulation of single strand break repair; ISO:RGD.
DR   GO; GO:0010990; P:regulation of SMAD protein complex assembly; IMP:RGD.
DR   GO; GO:1904044; P:response to aldosterone; IEP:RGD.
DR   GO; GO:0010332; P:response to gamma radiation; IEP:RGD.
DR   GO; GO:0023019; P:signal transduction involved in regulation of gene expression; IMP:BHF-UCL.
DR   GO; GO:0000723; P:telomere maintenance; ISO:RGD.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0050882; P:voluntary musculoskeletal movement; ISO:RGD.
DR   Gene3D; 1.20.142.10; -; 1.
DR   Gene3D; 2.20.140.10; -; 1.
DR   Gene3D; 2.20.25.630; -; 1.
DR   Gene3D; 3.30.1740.10; -; 2.
DR   Gene3D; 3.40.50.10190; -; 1.
DR   InterPro; IPR001357; BRCT_dom.
DR   InterPro; IPR036420; BRCT_dom_sf.
DR   InterPro; IPR012982; PADR1.
DR   InterPro; IPR038650; PADR1_dom_sf.
DR   InterPro; IPR008288; PARP.
DR   InterPro; IPR012317; Poly(ADP-ribose)pol_cat_dom.
DR   InterPro; IPR004102; Poly(ADP-ribose)pol_reg_dom.
DR   InterPro; IPR036616; Poly(ADP-ribose)pol_reg_dom_sf.
DR   InterPro; IPR036930; WGR_dom_sf.
DR   InterPro; IPR008893; WGR_domain.
DR   InterPro; IPR001510; Znf_PARP.
DR   InterPro; IPR036957; Znf_PARP_sf.
DR   Pfam; PF00533; BRCT; 1.
DR   Pfam; PF08063; PADR1; 1.
DR   Pfam; PF00644; PARP; 1.
DR   Pfam; PF02877; PARP_reg; 1.
DR   Pfam; PF05406; WGR; 1.
DR   Pfam; PF00645; zf-PARP; 2.
DR   PIRSF; PIRSF000489; NAD_ADPRT; 1.
DR   SMART; SM00292; BRCT; 1.
DR   SMART; SM01335; PADR1; 1.
DR   SMART; SM00773; WGR; 1.
DR   SMART; SM01336; zf-PARP; 2.
DR   SUPFAM; SSF142921; SSF142921; 1.
DR   SUPFAM; SSF47587; SSF47587; 1.
DR   SUPFAM; SSF52113; SSF52113; 1.
DR   PROSITE; PS50172; BRCT; 1.
DR   PROSITE; PS51060; PARP_ALPHA_HD; 1.
DR   PROSITE; PS51059; PARP_CATALYTIC; 1.
DR   PROSITE; PS00347; PARP_ZN_FINGER_1; 2.
DR   PROSITE; PS50064; PARP_ZN_FINGER_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ADP-ribosylation; Chromosome; DNA damage;
KW   DNA repair; DNA-binding; Glycosyltransferase; Isopeptide bond;
KW   Metal-binding; NAD; Nucleus; Phosphoprotein; Reference proteome; Repeat;
KW   Transcription; Transcription regulation; Transferase; Ubl conjugation;
KW   Zinc; Zinc-finger.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   CHAIN           2..1014
FT                   /note="Poly [ADP-ribose] polymerase 1"
FT                   /id="PRO_0000211321"
FT   DOMAIN          386..477
FT                   /note="BRCT"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00033"
FT   DOMAIN          554..630
FT                   /note="WGR"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          662..779
FT                   /note="PARP alpha-helical"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00398"
FT   DOMAIN          788..1014
FT                   /note="PARP catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00397"
FT   ZN_FING         9..93
FT                   /note="PARP-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00264"
FT   ZN_FING         113..203
FT                   /note="PARP-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00264"
FT   NP_BIND         862..864
FT                   /note="NAD"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UGN5"
FT   REGION          198..234
FT                   /note="Disordered"
FT                   /evidence="ECO:0000255"
FT   REGION          356..387
FT                   /note="Disordered"
FT                   /evidence="ECO:0000255"
FT   REGION          374..524
FT                   /note="Automodification domain"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   MOTIF           207..209
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   MOTIF           221..226
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   ACT_SITE        988
FT                   /note="For poly [ADP-ribose] polymerase activity"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   BINDING         871
FT                   /note="NAD; via carbonyl oxygen"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UGN5"
FT   BINDING         878
FT                   /note="NAD"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UGN5"
FT   BINDING         904
FT                   /note="NAD"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UGN5"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   MOD_RES         41
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   MOD_RES         97
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   MOD_RES         105
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   MOD_RES         131
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   MOD_RES         177
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   MOD_RES         179
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   MOD_RES         185
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   MOD_RES         275
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   MOD_RES         278
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   MOD_RES         388
FT                   /note="PolyADP-ribosyl aspartic acid"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   MOD_RES         408
FT                   /note="PolyADP-ribosyl glutamic acid"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         414
FT                   /note="PolyADP-ribosyl glutamic acid"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         436
FT                   /note="PolyADP-ribosyl glutamic acid"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         438
FT                   /note="PolyADP-ribosyl glutamic acid"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         445
FT                   /note="PolyADP-ribosyl glutamic acid"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         446
FT                   /note="PolyADP-ribosyl glutamic acid"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         457
FT                   /note="PolyADP-ribosyl glutamic acid"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         485
FT                   /note="PolyADP-ribosyl glutamic acid"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         489
FT                   /note="PolyADP-ribosyl glutamic acid"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   MOD_RES         492
FT                   /note="PolyADP-ribosyl glutamic acid"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   MOD_RES         500
FT                   /note="ADP-ribosylserine"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   MOD_RES         504
FT                   /note="ADP-ribosylserine"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   MOD_RES         507
FT                   /note="ADP-ribosylserine"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   MOD_RES         513
FT                   /note="PolyADP-ribosyl glutamic acid"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         514
FT                   /note="PolyADP-ribosyl glutamic acid"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         519
FT                   /note="ADP-ribosylserine"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   MOD_RES         520
FT                   /note="PolyADP-ribosyl glutamic acid"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         600
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   MOD_RES         621
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   MOD_RES         782
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   MOD_RES         786
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   CROSSLNK        192
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   CROSSLNK        203
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   CROSSLNK        203
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   CROSSLNK        250
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   CROSSLNK        468
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   CROSSLNK        487
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   CROSSLNK        487
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   CROSSLNK        512
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   CROSSLNK        528
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   CROSSLNK        748
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   CROSSLNK        748
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P09874"
FT   CONFLICT        639
FT                   /note="Y -> H (in Ref. 5; CAA46478)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        642
FT                   /note="E -> A (in Ref. 5; CAA46478)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        753
FT                   /note="N -> D (in Ref. 5; CAA46478)"
FT                   /evidence="ECO:0000305"
FT   STRAND          394..398
FT                   /evidence="ECO:0007744|PDB:2LE0"
FT   HELIX           406..416
FT                   /evidence="ECO:0007744|PDB:2LE0"
FT   STRAND          422..424
FT                   /evidence="ECO:0007744|PDB:2LE0"
FT   STRAND          427..431
FT                   /evidence="ECO:0007744|PDB:2LE0"
FT   HELIX           434..439
FT                   /evidence="ECO:0007744|PDB:2LE0"
FT   HELIX           442..449
FT                   /evidence="ECO:0007744|PDB:2LE0"
FT   STRAND          453..455
FT                   /evidence="ECO:0007744|PDB:2LE0"
FT   HELIX           458..465
FT                   /evidence="ECO:0007744|PDB:2LE0"
FT   HELIX           470..476
FT                   /evidence="ECO:0007744|PDB:2LE0"
SQ   SEQUENCE   1014 AA;  112660 MW;  BE1B6F2B29B887ED CRC64;
     MAEATERLYR VEYAKSGRAS CKKCSESIPK DSLRMAIMVQ SPMFDGKVPH WYHFSCFWKV
     GHSIRQPDTE VDGFSELRWD DQQKVKKTAE AGGVAGKGQH GGGGKAEKTL GDFAAEYAKS
     NRSTCKGCME KIEKGQMRLS KKMLDPEKPQ LGMIDRWYHP TCFVKNRDEL GFRPEYSASQ
     LKGFSLLSAE DKEALKKQLP AVKSEGKRKC DEVDGIDEVA KKKSKKGKDK ESSKLEKALK
     AQNELVWNIK DELKKACSTN DLKELLIFNQ QQVPSGESAI LDRVADGMAF GALLPCKECS
     GQLVFKSDAY YCTGDVTAWT KCMVKTQNPS RKEWVTPKEF REISYLKKLK IKKQDRLFPP
     ESSAPAPPAP PVSITSAPTA VNSSAPADKP LSNMKILTLG KLSQNKDEAK AMIEKLGGKL
     TGSANKASLC ISTKKEVEKM SKKMEEVKAA NVRVVCEDFL QDVSASAKSL QELLSAHSLS
     SWGAEVKVEP GEVVVPKGKS AAPSKKSKGA VKEEGVNKSE KRMKLTLKGG AAVDPDSGLE
     HSAHVLEKGG KVFSATLGLV DIVKGTNSYY KLQLLESDKE SRYWIFRSWG RVGTVIGSNK
     LEQMPSKEDA VEHFMKLYEE KTGNAWHSKN FTKYPKKFYP LEIDYGQDEE AVKKLAVKPG
     TKSKLPKPVQ ELVGMIFDVE SMKKALVEYE IDLQKMPLGK LSRRQIQAAY SILSEVQQAV
     SQGSSESQIL DLSNRFYTLI PHDFGMKKPP LLNNTDSVQA KVEMLDNLLD IEVAYSLLRG
     GSDDSSKDPI DVNYEKLKTD IKVVDRDSEE AEVIRKYVKN THATTHNAYD LEVIDIFKIE
     REGESQRYKP FRQLHNRRLL WHGSRTTNFA GILSQGLRIA PPEAPVTGYM FGKGIYFADM
     VSKSANYCHT SQGDPIGLIL LGEVALGNMY ELKHASHISK LPKGKHSVKG LGKTAPDPSA
     SITLDGVEVP LGTGIPSGVN DTCLLYNEYI VYDIAQVNLK YLLKLKFNFK TSLW
//
